Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 8
Submit an article Journal homepage
155
Views
7
CrossRef citations to date
0
Altmetric
Theme: Stroke - Review

Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator

Vijay K Sharma Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, 119074 Singapore. [email protected]; Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, 119074 Singapore. [email protected]; Yong Loo Lin School of Medicine, National University of Singapore, Singapore
,
Ghulam Kawnayn Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, 119074 Singapore; Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, 119074 Singapore
&
Nabin Sarkar Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, 119074 Singapore; Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, 119074 Singapore
Pages 895-902 | Published online: 09 Jan 2014

References

  • No authors listed. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581–1587 (1995).
  • Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 363(9411), 768–774 (2004).
  • Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317–1329 (2008).
  • Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. 4, CD000213 (2009).
  • Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch. Neurol. 61(7), 1066–1070 (2004).
  • Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 371(9624), 1612–1623 (2008).
  • Brott TG, Haley EC, Levy DE et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23(5), 632–640 (1992).
  • Haley EC, Levy DE, Brott TG et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 23(5), 641–645 (1992).
  • Khatri P, Broderick JP, Pancioli AM. Risk of thrombolysis-associated intracerebral hemorrhage: the need to compare apples with apples. Stroke 36(6), 1109–1110 (2005).
  • Mori E, Yoneda Y, Tabuchi M et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42(5), 976–982 (1992).
  • Yamaguchi T, Kikuchi H, Hayakawa H et al. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In: Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ (Eds). Springer-Verlag, Tokyo, Japan, 223–229 (1995).
  • Shaw GJ, Meunier JM, Lindsell CJ, Pancioli AM, Holland CK. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb. Res. 126(4), 305–311 (2010).
  • Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb. Haemost. 87(3), 544–546 (2002).
  • Yamaguchi T, Mori E, Minematsu K et al.; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37(7), 1810–1815 (2006).
  • Toyoda K, Koga M, Naganuma M et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients; general outcomes and prognostic factors from the SAMURAI register. Stroke 40(11), 3591–3595 (2009).
  • Nakagawara J, Minematsu K, Okada Y et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 41(9), 1984–1989 (2010).
  • Pandian JD, Srikanth V, Read SJ, Thrift AG. Poverty and stroke in India: a time to act. Stroke 38(11), 3063–3069 (2007).
  • Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study – a randomized controlled trial. JAMA 282(21), 2019–2026 (1999).
  • Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 274(13), 1017–1025 (1995).
  • Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352(9136), 1245–1251 (1998).
  • The IST-3 collaborative group; Sandercock P, Wardlaw JM, Lindley RI et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST 3]): a randomised controlled trial. Lancet 379(9834), 2352–2362 (2012).
  • Wahlgren N, Ahmed N, Da’valos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST): an observational study. Lancet 369(9558), 275–282 (2007).
  • Topakian R, Brainin M, Eckhardt R et al.; SITS-Austria group. Thrombolytic therapy for acute stroke in Austria: data from the Safe Implementation of Thrombolysis in Stroke (SITS) register. Eur. J. Neurol. 18(2), 306–311 (2011).
  • Kobayashi A, Czlonkowska A, Ahmed N et al.; SITS Poland Collaborative Group. Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry. Acta Neurol. Scand. 122(4), 229–236 (2010).
  • Simpson MA, Dewey HM, Churilov L et al. Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002–2008). Med. J. Aust. 193(8), 439–443 (2010).
  • Yoneda Y, Yamamoto S, Hara Y et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin. Neurol. Neurosurg. 109(7), 567–570 (2007).
  • Sharma VK, Ng KW, Venketasubramanian N, Teoh HL, Chan BP. Intravenous thrombolysis for acute ischemic stroke in Asia. Expert Rev. Neurother. 12(2), 209–217 (2012).
  • Mori E, Minematsu K, Nakagawara J et al. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke 41(3), 461–465 (2010).
  • Padma MV, Singh MB, Bhatia R et al. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol. India 55(1), 46–49 (2007).
  • Salam KA, Ummer K, Pradeep Kumar VG, Noone ML, Laila A, Ragini J. Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008. J. Clin. Neurosci. 16(10), 1276–1278 (2009).
  • Sharma SR, Sharma N. Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective. Ann. Indian Acad. Neurol. 11(4), 221–224 (2008).
  • Boddu DB, Prasad RG, Bandaru VCSS et al. Predictors of major neurologic improvement after Intravenous thrombolysis in acute ischemic stroke: a hospital based study from Hyderabad, India. Ann. Indian Acad. Neurol. 58(3), 403–406 (2010).
  • Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: the first prospective evaluation. Clin. Neurol. Neurosurg. 108(6), 549–552 (2006).
  • Muengtaweepongsa S, Dharmasaroja P, Kummark U. Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country. J. Stroke Cerebrovasc. Dis. 21(1), 42–46 (2012).
  • Dharmasaroja PA, Dharmasaroja P, Muengtaweepongsa S. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis. J. Neurol. Sci. 300(1–2), 74–77 (2011).
  • Zhou XY, Wanga SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J. Clin. Neurosci. 17(8), 988–992 (2010).
  • Pan SM, Liu JF, Liu M et al. Efficacy and safety of a modified intravenous recombinant tissue plasminogen activator regimen in Chinese patients with acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 22, 690–693 (2013).
  • Hsu YC, Sung SF, Ong CT, Wu CS, Su YH. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. Acta Neurol. Taiwan. 18(1), 14–20 (2009).
  • Chao AC, Hsu HY, Chung CP et al. Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients. The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study. Stroke 41(5), 885–890 (2010).
  • Chen CH, Hsieh CY, Lai TB, Chuang MT, Chen WL, Sun MC. Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose. J. Thromb. Haemost. 10(7), 1270–1275 (2012).
  • Sharma VK, Tsivgoulis G, Tan JH, Ong BKC, Chan BPL, Teoh HL. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J. Stroke Cerebrovasc. Dis. 19(6), 424–430 (2010).
  • Nguyen TH, Truong ATL, Ngo MB et al. Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam thrombolysis registry. Eur. J. Neurol. 17(9), 1188–1192 (2010).
  • Lau AY, Soo YO, Graham CA et al. An expedited stroke triage pathway is the key to shortening the door-to-needle time in delivery of thrombolysis treatment. Hong Kong Med. J. 16(6), 455–462 (2010).
  • Wasay M, Barohi H, Malik A, Yousuf A, Awan S, Kamal AK. Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan. Neurol. Sci. 31(2), 223–225 (2010).
  • Adams HP, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1), 35–41 (1993).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.